Transurethral resection for muscle-invasive bladder cancer.
The perioperative morbidity of local radical transurethral resection performed in 103 patients with muscle-invasive bladder cancer (T2-T3a) was 20%, their mortality 1%. The three- and five-year survivals were 54% and 36%, respectively. Within 5 years after transurethral resection of primary tumours relapses were encountered in 46%, progression in 33% of the cases. The cause of death was tumour in 29% of the patients, and some other disease in 35%. The full thickness transurethral resection combined with adjuvant treatment may be an alternative to cystectomy in selected cases of T2-T3a bladder cancer.
Kondás
J
J
Department of Urology, Municipal Péterffy Sándor Street Hospital, Budapest, Hungary.
Váczi
L
L
Szecsó
L
L
Kondér
G
G
D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009132:Muscles / Q000473:pathology; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D009367:Neoplasm Staging; D013514:Surgical Procedures, Operative / Q000379:methods; D015996:Survival Rate; D014521:Urethra; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*